Therapeutic Dendritic Cell− Based Cancer Vaccines: The State of the Art

MM Strioga, T Felzmann, DJ Powell Jr… - Critical Reviews™ in …, 2013 - dl.begellhouse.com
Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

Modified polynucleotides encoding granulysin

T Chakraborty, A De Fougerolles - US Patent 9,216,205, 2015 - Google Patents
2014-03-03 Assigned to MODERNA THERAPEUTICS, INC. reassignment MODERNA
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …

Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity

J Dannull, DT Lesher, R Holzknecht… - Blood, The Journal …, 2007 - ashpublications.org
The process of dendritic cell (DC) maturation, critical for effective DC-based immunotherapy,
also alters the proteasome such that peptides presented in the context of HLA class I are …

Prospects and challenges of building a cancer vaccine targeting telomerase

RH Vonderheide - Biochimie, 2008 - Elsevier
Despite their origin from self-tissue, tumor cells can be immunogenic and trigger immune
responses that can profoundly influence tumor growth and development. Clinically, it may be …

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4

RM Cisco, Z Abdel-Wahab, J Dannull… - The Journal of …, 2004 - journals.aai.org
Maturation of dendritic cells (DC) is critical for the induction of Ag-specific immunity. Ag-
loaded DC matured with LPS, which mediates its effects by binding to Toll-like receptor 4 …

An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine

J Harris, T Monesmith, A Ubben, M Norris… - … et Biophysica Acta (BBA …, 2005 - Elsevier
Use of antigen encoding RNA transfected Dendritic cells in the field of cancer
immunotherapy has been well established. The use of RNA overcomes limitations inherent …

Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL That Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic …

F Morandi, S Chiesa, P Bocca, E Millo, A Salis, M Solari… - Neoplasia, 2006 - Elsevier
Several observations suggest a potential role of T-cell-mediated immunity in the control of
neuroblastoma (NB). However, the generation of NB-specific cytotoxic T lymphocytes (CTL) …

Modified polynucleotides for the production of cosmetic proteins and peptides

S Bancel, EYC Huang - US Patent 9,878,056, 2018 - Google Patents
2014-12-18 Assigned to MODERNA THERAPEUTICS, INC. reassignment MODERNA
THERAPEUTICS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING …

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

JP Schrum, S Siddiqi, K Ejebe - US Patent 10,064,959, 2018 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Cellular immunotherapy with dendritic cells in cancer: current status

A Nencioni, P Brossart - Stem Cells, 2004 - academic.oup.com
Dendritic cells (DCs) are specialized antigen‐presenting cells whose immunogenicity leads
to the induction of antigen‐specific immune responses. DCs can easily be generated ex vivo …